In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.
In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, a hematologist at the Mayo Clinic Comprehensive Cancer Center and professor of Medicine at the Mayo Clinic College of Medicine, discusses the latest advances in the treatment of diffuse large B-cell lymphoma (DLBCL).
After administering radiation therapy in the frontline setting to patients with DLBCL for many years, PET-adapted therapeutic approaches were introduced. Then, across roughly 25 clinical trials, explains Habermann, investigators explored the efficacy and safety of the rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), which became the standard of care regimen for DLBCL treatment.
In recent years, clinical trials are assessing targeted therapies and immunotherapies, including chimeric antigen receptor T cells with the goal of improving on the standard of care.
According to Habermann, the most important thing to focus on with the next wave of therapies is curing 100% of patients with DLBCL. Currently, this is only possible in 65% of patients who received R-CHOP, explains Habermann. Improvement in both systemic and radiation therapies signal hope that the field is moving in the right direction, Haberman notes.
Glofitamab/Chemo Leads to Survival Benefit in Transplant-Ineligible R/R DLBCL
July 3rd 2024A study found that glofitamab plus gemcitabine and oxaliplatin significantly improved survival in patients with relapsed/refractory diffuse large B-cell lymphoma who were not eligible for stem cell transplant.
Read More
Different Options Discussed for DLBCL in Later-Lines of Treatment
June 13th 2024During a Case-Based Roundtable® event, Matthew Ulrickson, MD, considered treatments for patients with relapsed/refractory diffuse large B-cell lymphoma with event participants in the second article of a 2-part series.
Read More
Early Data Shows Axi-Cel’s Potential in Treating R/R Primary and Secondary CNS Lymphomas
June 13th 2024Findings from a phase 1 trial presented at ASCO showed that axicabtagene ciloleucel was safe with clinical activity seen among patients with relapsed/refractory primary and secondary central nervous system lymphoma.
Read More